Athira Pharma Debt/Equity Ratio 2019-2024 | ATHA

Athira Pharma debt/equity ratio from 2019 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Athira Pharma Debt/Equity Ratio 2019-2024 | ATHA

Athira Pharma debt/equity ratio from 2019 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$169.2B
Vertex Pharmaceuticals (VRTX)$121.3B
Gilead Sciences (GILD)$108.6B
Bristol Myers Squibb (BMY)$107.6B
Regeneron Pharmaceuticals (REGN)$103.8B
CSL (CSLLY)$94B
GSK (GSK)$78.7B
Alnylam Pharmaceuticals (ALNY)$37.9B
Argenex SE (ARGX)$33.4B
Biogen (BIIB)$26.7B
BioNTech SE (BNTX)$26.4B
Illumina (ILMN)$22.8B
BeiGene (BGNE)$21.5B
Moderna (MRNA)$20.5B
Genmab (GMAB)$15B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$13B
Incyte (INCY)$12.6B
Vaxcyte (PCVX)$12.5B
Sarepta Therapeutics (SRPT)$12.4B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$11B
QIAGEN (QGEN)$9.6B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Revolution Medicines (RVMD)$8.1B
Exelixis (EXEL)$8.1B
Legend Biotech (LEGN)$8B
Intra-Cellular Therapies (ITCI)$7.9B
Ascendis Pharma (ASND)$7.7B